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Abstract
Objective To determine whether the use of age adapted D-dimer cut-off
values can be translated to primary care patients who are suspected of
deep vein thrombosis.
Design Retrospective, cross sectional diagnostic study.
Setting 110 primary care doctors affiliated with three hospitals in the
Netherlands.
Participants 1374 consecutive patients (936 (68.1%) aged >50 years)
with clinically suspected deep vein thrombosis.
Main outcome measures Proportion of patients with D-dimer values
below two proposed age adapted cut-off levels (age in years×10 μg/L
in patients aged >50 years, or 750 μg/L in patients aged ≥60 years), in
whom deep vein thrombosis could be excluded; and the number of false
negative results.
Results Using the Wells score, 647 patients had an unlikely clinical
probability of deep vein thrombosis. In these patients (at all ages), deep
vein thrombosis could be excluded in 309 (47.8%) using the age
dependent cut-off value compared with 272 (42.0%) using the
conventional cut-off value of 500 μg/L (increase 5.7%, 95% confidence
interval 4.1% to 7.8%). This exclusion rate resulted in 0.5% and 0.3%
false negative cases, respectively (increase 0.2%, 0.004% to 8.6%).The
increase in exclusion rate by using the age dependent cut-off value was
highest in the oldest patients. In patients older than 80 years, deep vein
thrombosis could be safely excluded in 22 (35.5%) patients using the
age dependent cut-off value compared with 13 (21.0%) using the
conventional cut-off value (increase 14.5%, 6.8% to 25.8%). Compared
with the age dependent cut-off value, the cut-off value of 750 μg/L had
a similar exclusion rate (307 (47.4%) patients) and false negative rate
(0.3%).
Conclusions Combined with a low clinical probability of deep vein
thrombosis, use of the age dependent D-dimer cut-off value for patients
older than 50 years or the cut-off value of 750 μg/L for patients aged 60
years and older resulted in a considerable increase in the proportion of
patients in primary care in whom deep vein thrombosis could be safely
excluded, compared with the conventional cut-off value of 500 μg/L.
Introduction
Venousthromboembolism(pulmonaryembolismanddeepvein
thrombosis) is a common disease in elderly people. In fact, the
annualincidenceofvenousthromboembolismrisessharplywith
age, from an insignificant rate in children (less than five cases
per 100 000 people) to 450-900 cases per 100 000 people in
those older than 80 years.
1 2 Short term mortality of venous
thromboembolism also increases with age, and can occur in
more than 15% of elderly patients.
1 3 Hence, especially in this
age group, accurate and timely diagnosis of venous
thromboembolism can be lifesaving.
4 However, comorbidity
often camouflages typical signs and symptoms of venous
thromboembolism, and the diagnosis of deep vein thrombosis
and pulmonary embolism is difficult and is often missed in
elderly populations.
4
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Research
RESEARCHAccurate exclusion of venous thromboembolism can be
improved by the additional use of tests to measure the
concentration of D-dimer (a degradation product of fibrin).
Negative test results are commonly used to rule out patients
with suspected venous thromboembolism and a low clinical
probability.
5 6 However, D-dimer concentration increases with
age and its specificity for venous thromboembolism decreases
inelderlypatients.
7 8Thiseffectleadstomorefalsepositivetest
resultsinelderlypeople(thatis,detectionofalowerproportion
of these patients in whom venous thromboembolism can be
excluded). As a result, many elderly patients could be referred
to hospital unnecessarily for additional testing.
9-11 Many
physicians would prefer to rule out venous thromboembolism
(especiallyinfrailelderlypatients)withoutanoftenburdensome
referral.
To improve the diagnostic strategy of suspected venous
thromboembolism in elderly patients, Douma and colleagues
10
recently derived and internally validated an age dependent,
D-dimer cut-off value for those with clinically suspected
pulmonaryembolisminsecondarycare.Theresearchersdefined
this cut-off value as age (years)×10 μg/L in patients older than
50 years (for example, a patient aged 73 years would have a
cut-off value of 73×10=730 μg/L). Use of this formula doubled
the proportion of patients older than 70 years in whom
pulmonary embolism could be excluded, without hampering
the false negative rate of such an approach.
10 In addition, Haas
and colleagues proposed an alternative, fixed cut-off value of
750 μg/L in patients aged 60 years and older who were referred
to secondary care with symptoms of deep vein thrombosis.
12
Thisproposedcut-offvaluealsoyieldedanincreasedproportion
of patients in whom deep vein thrombosis could be correctly
excluded.
The age dependent value and fixed value can both help safely
exclude venous thromboembolism in a large proportion of frail
elderly patients without the need for burdensome referrals for
furtherdiagnosticwork-up.However,theagedependentcut-off
value was not validated for use in patients suspected of deep
vein thrombosis. Since deep vein thrombosis and pulmonary
embolism can be seen as expressions of the same disease,
13 we
hypothesised that use of the age dependent cut-off value could
beextrapolatedtopatientswithsuspecteddeepveinthrombosis.
Furthermore, both the age dependent value and the fixed value
were not validated in primary care. Before implementing these
different cut-off values for patients with suspected deep vein
thrombosis, a formal validation study would be needed.
14 15
Therefore, we aimed to compare the exclusion rate and false
negative rate of both proposed cut-off values with those of the
conventionalcut-offvalueof500μg/Lfortheexclusionofdeep
vein thrombosis in a large cohort of patients with clinically
suspected deep vein thrombosis in primary care.
Methods
Patients
We performed a retrospective analysis of data from two
originallyprospective,diagnosticaccuracystudiesthatincluded
2086 primary care patients suspected of deep vein thrombosis.
The first study was a derivation study for a new diagnostic rule
to determine the presence or absence of deep vein thrombosis
in primary care patients (n=1295).
16 On behalf of validation of
the newly derived rule, researchers extended the study within
the same setting and added 791 patients to the initial cohort
9 17
(so-called temporal validation).
18 19 The characteristics of these
studies have been published previously.
9 16-17
In short, the studies were conducted among 110 primary care
physicians affiliated with three hospitals in the Netherlands,
between1January2002and1January2006.Thethreeadhering
hospitals participated in a diagnostic programme in which the
primarycarephysiciansuseddiagnosticfacilitiesofthehospital
without referring the patient to a hospital specialist. All
consecutive adults with a clinical suspicion of deep vein
thrombosis were eligible for inclusion. Suspicion of deep vein
thrombosiswasbasedonswelling,redness,orpainofthelower
extremities.Thestudyexcludedpatientsifsymptomsandsigns
lasted for more than 30 days and if there was a suspicion of
pulmonaryembolism.Thestudyalsoexcludedpatientsreceiving
anticoagulant treatment at presentation or who were unwilling
to participate in the studies. Written informed consent was
obtained from patients. The studies were approved by the local
ethics review boards of the University Medical Center Utrecht,
the Netherlands.
Each patient was assessed for the clinical probability score
accordingtoWells,
21andmeasuredforplasmaD-dimer(VIDAS
(Biomerieux) or Tinaquant (Roche) assays). On the same day,
allpatientsunderwentreferencetestingbyrepeatedcompression
ultrasonography of the symptomatic leg, performed with a real
time, B mode, linear array sonographic scanner at 5.0-7.5 MHz
(systemVGE/Sonotion).
22Theentireproximaldeepveinsystem
was explored for compressibility. In patients with a normal
ultrasonography, the test was repeated at day seven. Deep vein
thrombosis was established if at least one of the deep veins in
the legs was not completely compressible at one of the two
compression ultrasonography examinations, or excluded after
two negative examinations (that is, revealing completely
compressibleveinsofthelegs).Theperformersandinterpreters
of the examinations (board certified radiologists) were blinded
to information on the patient’s history, physical examination,
and D-dimer test results.
Data analysis
Forthecurrentanalysis,weincludedonlyparticipantsforwhom
D-dimer test results were available (n=1374). We calculated
the clinical probability of deep vein thrombosis for all patients
usingtheWellsclinicalpredictionrule.Patientswereclassified
according to the dichotomised Wells score as “likely” (≥2) or
“unlikely” (≤1) to have deep vein thrombosis.
21 We
dichotomised D-dimer concentrations by using the age
dependent cut-off value proposed by Douma and colleagues in
patients older than 50 years (age in years×10 µg/L)
10; the fixed
cut-off value of 750 μg/L in patients aged 60 years and older,
as proposed by Haas and colleagues
12; and the conventional
cut-off value of 500 μg/L in patients of all ages.
21
For patients with an unlikely clinical probability of deep vein
thrombosis according to the Wells score, we calculated the
proportion in whom deep vein thrombosis could be excluded
(basedonanunlikelyclinicalprobabilityandanegativeD-dimer
testresultusingthedifferentcut-offvalues).Wealsocalculated
the corresponding proportions of false negative results—that
is, prevalence of deep vein thrombosis (as established by
compression ultrasonography) among patients with an unlikely
clinical probability and a negative test result. We calculated the
number of patients needed to undergo a D-dimer assay to
excludedeepveinthrombosisinonepatient(thatis,thenumber
of patients needed to test) by dividing 1 by the proportion of
patientswithanegativetestresultandindeedwithoutdeepvein
thrombosis (that is, the proportion of true negatives).
23 We did
analyses with SPSS version 17.0, and calculated appropriate
95% confidence intervals using a programmable calculator
application in Microsoft Office, Excel 2003.
24
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Table 1⇓ shows the baseline characteristics of all included
participantswithavailableD-dimerresults(n=1374).Meanage
was 59.3 years (standard deviation 17.4), and most participants
wereolderthan50years(936/1374,68.1%).Prevalenceofdeep
vein thrombosis was 19.7% (270/1374). Of 1374 participants
of all ages, 647 (47.1%) had an unlikely clinical probability of
deep vein thrombosis (Wells score ≤1; table 2 ⇓). Using the
conventional D-dimer cut-off value of 500 μg/L, 272 of these
647 participants had negative test results (42.0%, 95%
confidenceinterval38.2%to46.0%,numberneededtotest2.4).
Twoofthese272participantshaddeepveinthrombosis,afalse
negative proportion of 0.3% (0.04% to 1.1%).
Using the age dependent cut-off value (age in years×10 μg/L
for patients aged >50 years), we could exclude deep vein
thrombosis in 309 patients (47.8%, 95% confidence interval
43.9% to 51.7%; table 2), which was an additional 37 patients
(absolute increase 5.7%, 4.1% to 7.8%, number needed to test
2.1) compared with the convention cut-off value of 500 μg/L.
The age dependent cut-off value missed one patient more than
theconventionalcut-offvalue(threemissedcases(falsenegative
proportion0.5%,0.01%to1.3%)vtwo(0.3%,0.04%to1.1%),
respectively; increase 0.2% (0.004% to 8.6%)).
Using the fixed cut-off value of 750 μg/L in participants aged
60 years and older, we could exclude deep vein thrombosis in
307 patients (47.4%, 95% confidence interval 43.5% to 51.4%,
number needed to test 2.1; table 2). Compared with the
conventional cut-off value of 500 μg/L, use of the fixed cut-off
value could exclude deep vein thrombosis in an additional 35
patients (5.4%, 3.8% to 7.4%). The fixed cut-off value did not
miss any extra cases, and the false negative rate remained at
0.3% (0.04% to 1.1%).
Effect of age on efficiency and safety of
different D-dimer cut-off values
Use of the age dependent cut-off value (at age >50 years) and
cut-off value of 750 μg/L (at age ≥60 years) instead of the
conventional cut-off value of 500 μg/L (at all ages) showed an
increasing efficiency (that is, a higher proportion of patients in
whomdeepveinthrombosiscouldbeexcluded)withincreasing
age, without compromising safety (that is, the false negative
proportion of patients). The proportion of patients aged 70-80
years in whom deep vein thrombosis could be excluded
increasedfrom30.6%(95%confidenceinterval22.2%to40.1%;
table 2) using the conventional cut-off value to 45.0% (35.6%
to 54.8%) using the age dependent cut-off value and 45.9%
(36.4%to55.7%)usingthecut-offvalueof750μg/L.Inpatients
older than 80 years, these proportions were 21.0% (11.7% to
33.2%),35.5%(23.7%to48.7%),and33.9%(22.3%to47.0%),
respectively.
Performance of age adapted cut-off values
with different D-dimer assays
Since the original studies used two different D-dimer assays
(Tinaquant or VIDAS),
9 16-17 we did separate analyses for these
two assays. We found no differences between the two assays
infalsenegativeratesforanyofthestudiedcut-offvalues(table
3⇓). However, irrespective of the cut-off value applied, deep
veinthrombosiswasruledoutmorefrequentlyintheTinaquant
assay group than in the VIDAS assay group.
Discussion
Thisstudyshowedthattheuseofanagedependentcut-offvalue
(age×10 μg/L in patients aged >50 years) and a fixed cut-off
value (750 μg/L in patients aged ≥60 years), combined with an
unlikely clinical probability of deep vein thrombosis, resulted
inaconsiderableincreaseintheproportionofsuspectedelderly
patients in primary care in whom deep vein thrombosis could
be safely and correctly excluded, compared with use of the
conventional cut-off value (500 μg/L at all ages). Use of these
proposed D-dimer cut-off values reduced the number needed
to test by compression ultrasonography. This increase in
diagnostic efficiency rose with age, notably in the eldest group
of elderly patients. These findings are important, since further
diagnostictestingcanthusbeavoidedintheseoftenfrailelderly
patients.
Strengths and limitations of the study
This study provides an external validation of two age adapted,
D-dimer cut-off values previously proposed in secondary care
patientswithsuspectedvenousthromboembolism,andtranslates
these results to a large cohort of patients in primary care with
suspected deep vein thrombosis.
This study had some limitations. D-dimer values were missing
in 712 of 2086 participants in the original studies, because only
dichotomised D-dimer values (high v low) were displayed by
the laboratories in the early inclusion phase. Therefore, the
availability of the D-dimer values was time dependent. Time
can change the nature of study populations. For example, a
tendency for incidence of venous thromboembolism to fall in
suspected patients over time has been reported.
2 Therefore, we
analysed whether the absence versus presence of a D-dimer
value was related to observed patient characteristics. Most
baseline characteristics (11 of 14) were the same in patients
with and without available D-dimer values (web appendix 1);
the prevalence of deep vein thrombosis and the mean Wells
score also did not differ between the two groups (deep vein
thrombosis 19.7% v 20.4%, P=0.698; mean Well score 1.66
(standard deviation 1.97) v 1.74 (2.20), P=0.658). Therefore,
we believe that the exclusion of the patients with missing
D-dimer values was probably not related to patient
characteristics and thus did not bias our results.
We also repeated the entire analysis with the missing D-dimer
values imputed, using multiple imputation techniques (web
appendix 2). This advanced strategy deals with missing values,
andisgenerallypreferredovercompletecaseanalysis.Inshort,
we based a multiple imputation regression model on the
observed D-dimer values and corresponding patient
characteristics. We then used this model to estimate missing
valuesaccordingtotheobservedpatient’scharacteristics.
25This
analysis yielded the same results sustaining the inferences of
the complete case analysis, which further confirmed our
assumption that the study findings would not change if the
missing D-dimer values had been present.
Another limitation was that we used two different laboratory
techniques—VIDAS, an enzyme linked immunosorbent assay
(ELISA),andTinaquant,alatexagglutationtest.Althoughassay
dependent thresholds have been suggested previously,
26 27 we
based our analysis on a conventional cut-off point of 500 μg/L
for both assays. After stratifying for type of assay, we found no
differences in safety between the two tests, irrespective of the
cut-off level applied (table 3). However, deep vein thrombosis
could be ruled out more frequently in patients in the Tinaquant
assay group than in those in the VIDAS group. These findings
accord with those of Di Miso and colleagues,
27 who reported a
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the VIDAS test, compared with the Tinaquant test.
We also used serial compression ultrasonography as the
reference test. Owing to its non-invasiveness and its accuracy
runningclosetothegoldstandard,compressionultrasonography
has largely replaced venography in current medical practice.
However, ultrasonography has shown a missed diagnosis rate
of0.57%(pooledmeta-analysis,95%confidenceinterval0.25%
to0.89%)inpatientswithdeepveinthrombosis.
28Tolowerthis
misclassification rate, we by design repeated the compression
ultrasonography at day seven. However, the true safety of the
proposed D-dimer cut-off values might be slightly lower than
that based on the present analysis. Moreover, the
misclassification rate is known to be lower in patients with a
low clinical probability of deep vein thrombosis (0.29%, 0% to
0.70%).
28Thecurrentanalysis,however,includedonlypatients
withan“unlikely”clinicalprobability.Hence,anypossiblebias
induced by our choice of reference test would probably not
change the presented conclusions of our analysis.
We also caution the interpretation of our findings in patients
older than 80 years, since the number of this subgroup was
rathersmall.Finally,althoughthedatawereoriginallycollected
inaprospectivemanner,thisstudywasaretrospectiveanalysis.
Comparison with other studies
Douma and colleagues recently derived the age dependent
cut-off value in three cohorts of patients with suspected
pulmonary embolism (total of 5132 participants). They found
a similar increase in the proportion of patients in whom venous
thromboembolismcouldbeexcluded(increasesof6.3%,5.1%,
and 6.2% in derivation set, and validation sets 1 and 2,
respectively), compared with the current study (5.7%).
10
Our results also accord with the findings of Haas and
colleagues,
12 who found a similar although slightly higher
increase in exclusion rate in suspected patients older than 60
years in secondary care (12.8%). This small difference in
increase can probably be explained by differences in the
spectrum of patients (the range of comorbidities, the clinical
setting, and previous test probability) between our study and
theHaasstudy.Variationsinpatientspectrumhavebeenlinked
with variations in disease prevalence as well as variations in
diagnostic test accuracy.
29 30 In the Haas study, the prevalence
of deep vein thrombosis in their hospital setting was twice as
high as that found in our study (39.1% v 19.7%). This higher
prevalencecanemergefromashiftspectrumofpatients,towards
fewer patients with limited forms of deep vein thrombosis and
more patients with more manifested forms. This effect in turn
could have resulted in a somewhat lower exclusion rate with
the traditional cut-off value of 500 µg/L, and led to a higher
increaseintheexclusionrateafteruseoftheageadaptedcut-off
value, compared with our study.
Implications for clinicians and other
researchers
Afterderivationandvalidationinsecondarycare,
10 12weshowed
thatthetwoproposedageadaptedstrategiesforexcludingdeep
vein thrombosis using D-dimer measurement, have sustained
external validation in a large cohort of patients with suspected
deep vein thrombosis in primary care. Before implementing
these strategies in daily practice, a formal, prospective impact
study would need to assess the potential benefits of using an
age adapted, D-dimer cut-off value in daily patient care.
31 32
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RESEARCHTables
Table 1| Baseline characteristics of study patients with clinically suspected deep vein thrombosis. Data are no (%) of patients unless
specified otherwise
No of patients (N=1374)
59.3 (17.4) Age (years)*
863 (62.8) Female
61 (4.4) Active malignancy
194 (14.1) Paresis
168 (12.2) Recent surgery or bedridden
966 (70.3) Localised tenderness in deep vein system
596 (43.4) Entire leg swollen
551 (40.1) Calf distension ≥3 cm
838 (61.0) Pitting oedema
254 (18.5) Vein distension
672 (48.9) Alternative diagnosis present
284 (20.7) History of deep vein thrombosis
1.66 (2.0) Wells score*
270 (19.7) Suspected deep vein thrombosis
*Data are mean (standard deviation).
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RESEARCHTable 2| Proportion of patients with unlikely probability of deep vein thrombosis (Wells score ≤1) in whom deep vein thrombosis could be
excluded, by age group. Data are no (%, 95% CI) of patients, unless stated otherwise
Age group (years)
>80 70-80 60-70 50-60 All ages
85 74 66 55 57 Median age (years)
62 (9.6) 111 (17.2) 107 (16.5) 126 (19.5) 647 (100) No (%) of patients
Conventional cut-off value (500 µg/L)
13 (21.0 11.7 to 33.2) 34 (30.6, 22.2 to 40.1) 35 (32.7, 24.0 to 42.5) 59 (46.8, 37.9 to 55.9) 272 (42.0, 38.2 to 46.0) Patients below value
0 0 1 (0.9, 0.02 to 5.1) 0 2 (0.3, 0.04 to 1.1) Patients with false negative
result
4.8 3.3 3.1 2.1 2.4 Number of patients needed to
test
Age dependent cut-off value*
22 (35.5, 23.7 to 48.7) 50 (45.0, 35.6 to 54.8) 42 (39.3, 30.0 to 49.2) 64 (50.8, 41.7 to 59.8) 309 (47.8, 43.9 to 51.7) Patients below value
0 0 1 (0.9, 0.02 to 5.1) 1 (0.8, 0.02 to 4.3) 3 (0.5, 0.01 to 1.3) Patients with false negative
result
2.8 2.2 2.6 2.0 2.1 Number of patients needed to
test
Cut-off value (750 µg/L)†
21 (33.9, 22.3 to 47.0) 51 (45.9, 36.4 to 55.7) 45 (42.1, 32.6 to 52.0) 59 (46.8, 37.9 to 55.9) 307 (47.4, 43.5 to 51.4) Patients below value
0 0 1 (0.9, 0.02 to 5.1) 0 2 (0.3, 0.04 to 1.1) Patients with false negative
result
3.0 2.2 2.4 2.1 2.1 Number of patients needed to
test
Absolute increase in efficiency (% (95% CI))
14.5 (6.8 to 25.8) 14.4 (8.5 to 22.3) 6.5 (2.7 to 13.0) 3.9 (1.3 to 9.0) 5.7 (4.1 to 7.8) Using age dependent cut-off
value‡
12.9 (5.7 to 23.9) 15.3 (9.2 to 23.4) 9.3 (4.6 to 16.5) Not applicable 5.4 (3.8 to 7.4) Using cut-off value (750 µg/L)§
*Age (years)×10 µg/L for patients older than 50 years; conventional cut-off value 500 µg/L for younger patients.
†Cut-off value 750 µg/L for patients aged 60 years and older; conventional cut-off value 500 µg/L for younger patients.
‡Calculated as percentage of patients in whom deep vein thrombosis can be excluded by use of age dependent cut-off value minus percentage of patients in
whom deep vein thrombosis can be excluded by use of conventional cut-off value.
§Calculated as percentage of patients in whom deep vein thrombosis can be excluded by use of cut-off value 750 µg/L minus percentage of patients in whom
deep vein thrombosis can be excluded by use of conventional cut-off value.
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RESEARCHTable 3| Proportion of patients with unlikely probability of deep vein thrombosis (Wells score ≤1) in whom deep vein thrombosis could be
excluded, by D-dimer assay used. Data are no (%, 95% CI) of patients, unless stated otherwise
P Tinaquant (n=324) VIDAS test (n=323)
<0.001 54 60 Median age (years)
Conventional cut-off value (500 µg/L)
<0.001 166 (51.2, 45.6 to 56.8) 106 (32.8, 27.7 to 38.2) Below value
0.971 1 (0.3, 0.01 to 1.7) 1 (0.3, 0.01 to 1.7) With false negative result
Age dependent cut-off value*
<0.001 181 (55.9, 50.3 to 61.3) 128 (39.6, 34.2 to 45.2) Below value
0.527 1 (0.3, 0.01 to 1.7) 2 (0.6, 0.01 to 2.2) With false negative result
Cut-off value (750 µg/L)†
<0.001 179 (55.2, 49.7 to 60.7) 128 (39.6, 34.2 to 45.2) Below value
0.971 1 (0.3, 0.01 to 1.7) 1 (0.3, 0.01 to 1.7) With false negative result
Absolute increase in efficiency (% (95% CI))
Not significant 4.6 (2.6 to 7.5) 6.8 (4.3 to 10.1) Using age dependent cut-off value‡
Not significant 4.0 (2.1 to 6.8) 6.8 (4.3 to 10.1) Using cut-off value (750 µg/L)§
P values calculated by Pearson’s χ
2 two sided tests.
*Age (years)×10 µg/L for patients older than 50 years; conventional cut-off value 500 µg/L for younger patients.
†Cut-off value 750 µg/L for patients aged 60 years and older; conventional cut-off value 500 µg/L for younger patients.
‡Calculated as percentage of patients in whom deep vein thrombosis can be excluded by use of age dependent cut-off value minus percentage of patients in
whom deep vein thrombosis can be excluded by use of conventional cut-off value.
§Calculated as percentage of patients in whom deep vein thrombosis can be excluded by use of cut-off value 750 µg/L minus percentage of patients in whom
deep vein thrombosis can be excluded by use of conventional cut-off value.
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